Power of traumakine3 Apr 2020 09:52
1. Its interesting that the results of phase 2 were amazing:
"The selected pharmacodynamic marker for interferon-beta bioactivity showed clear dose response and the treatment target molecule (CD73) levels were induced during the dosing period. Most importantly, interferon-beta treatment significantly reduced the all-cause mortality at day 28, the primary end point of the study, compared to the control cohort (Bellingan et al. 2014, Lancet Respiratory Medicine). Traumakine was associated with an 81% reduction in odds of 28-day mortality"
2. The phase 3 had the issue of steroids.
3. YODA clarified that Traumakine works and steroids are not any good to use for
4. ARDS.
5. WHO accepted our findings
6. Now we ho head to head with large pharmas and their drugs to see if any can help.
7. Out of all thec12 drugs to treat ARDS in Covi paitents.. traumakine is the only one designed for that!